Nadim Ahmed

Nadim Ahmed serves as President and Chief Executive Officer of Cullinan Oncology, a biopharmaceutical company focused on modality-agnostic targeted oncology therapies. Nadim has over 25 years of leadership experience in oncology development and commercialization. Prior to serving as CEO of Cullinan, Nadim he served as President, Hematology at Bristol Myers Squibb and as President, Global Hematology & Oncology at Celgene. As President, Hematology at BMS, Nadim oversaw multiple product launches and served as a member of the company’s Leadership Team. Prior to BMS, Nadim served in leadership roles at Celgene across both development and commercialization functions. His career started at GSK where he held positions in clinical development, medical affairs, US commercial and global marketing. Throughout his career, Nadim has built expertise in various treatment modalities, including small molecules, biologics, and cell therapy in hematology and solid tumors. Nadim holds a Master of Science degree from Loughborough University, UK and a Bachelor of Science degree from University College London, UK. In 2023, he was awarded the Life Science Voice Top Industry Leader Award for his contributions to the industry. Nadim serves on the Board of Directors for Family Promise, a national non-profit organization helping families impacted by homelessness.